PTC Therapeutics, Inc.
General ticker "PTCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.3B (TTM average)
PTC Therapeutics, Inc. follows the US Stock Market performance with the rate: 32.7%.
Estimated limits based on current volatility of 1.7%: low 69.32$, high 71.75$
Factors to consider:
- Total employees count: 1047 as of 2025
- US accounted for 25.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Marketing authorization loss, Safety side effects, Sales/reimbursement failure, Supply chain disruptions
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [44.84$, 87.54$]
- 2026-12-31 to 2027-12-31 estimated range: [39.66$, 78.91$]
Financial Metrics affecting the PTCT estimates:
- Negative: with PPE of 10.0 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 49.49 > 18.77
- Positive: 6.77 < Operating cash flow per share per price, % of 11.52
- Positive: -14.39 < Investing cash flow per share per price, % of -13.96
- Positive: Return on assets ratio (scaled to [-100,100]) of 19.06 > 6.06
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 2.47 <= 3.34
- Negative: Shareholder equity ratio, % of -7.08 <= 18.97
Short-term PTCT quotes
Long-term PTCT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $937.82MM | $810.50MM | $1,730.65MM |
| Operating Expenses | $1,377.32MM | $1,113.08MM | $874.15MM |
| Operating Income | $-439.50MM | $-302.57MM | $856.51MM |
| Non-Operating Income | $-256.61MM | $-60.55MM | $-159.89MM |
| Interest Expense | $129.18MM | $166.99MM | $152.23MM |
| R&D Expense | $666.56MM | $534.48MM | $455.25MM |
| Income(Loss) | $-696.11MM | $-363.12MM | $696.62MM |
| Taxes | $-69.51MM | $0.18MM | $13.97MM |
| Net Income(Loss)* | $-626.60MM | $-363.30MM | $682.64MM |
| Stockholders Equity | $-818.55MM | $-1,098.07MM | $-205.31MM |
| Inventory | $30.58MM | $23.19MM | $79.65MM |
| Assets | $1,895.70MM | $1,705.02MM | $2,898.77MM |
| Operating Cash Flow | $-158.42MM | $-107.69MM | $711.20MM |
| Capital expenditure | $120.62MM | $74.25MM | $300.01MM |
| Investing Cash Flow | $-176.74MM | $44.18MM | $-861.98MM |
| Financing Cash Flow | $646.40MM | $255.87MM | $331.09MM |
| Earnings Per Share** | $-8.37 | $-4.73 | $8.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.